t
Oxford Biomedica PLC granted a total of 1,461,804 nil-cost share options to various directors and officers on April 7, 2026. These awards were made under the Company's 2024 Long Term Incentive Plan (LTIP), Restricted Share Units (RSU), and the 2024 Deferred Bonus Plan (DBP). Specifically, CEO Dr. Frank Mathias received 639,995 total awards and CFO Dr. Lucinda Crabtree received 243,465 total awards across these plans.
| Date | 8 Apr 2026 |
| Time | 17:18:41 |
| Category | Director/PDMR dealings |
| ID | 7055Z |
OXB
Grant of Awards
Oxford, UK - 08 April 2026: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, announces that on 07 April 2026, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Company's 2024 Long Term Incentive Plan ("LTIP"), including Restricted Share Units ("RSU") and the Company's 2024 Deferred Bonus Plan ("DBP").
As detailed in the recently published 2025 Directors' Remuneration Report:-
Re-instated LTIP awards: the LTIP grants in respect of 2024 and 2025, detailed below, reinstate the originally intended grant level for Dr. Frank Mathias and Dr. Lucinda Crabtree's 2024 and 2025 LTIP awards. The 2024 and 2025 LTIP awards were scaled back, primarily to manage the headroom available under the OXB share plans. The re-instatement honors the terms on which Dr. Mathias and Dr. Crabtree were recruited and reflects the Company's performance detailed in the 2025 Annual report and accounts. The re-instated LTIP awards remain subject to the original performance conditions and post-vesting holding periods, ensuring that the vesting of the awards is subject to the sustained strong performance of the business.
LTIP - Grant in respect of 2026: The 2026 LTIP metrics are 60% revenue, 40% Operating EBITDA margin, with target ranges in each case assessed on a constant currency basis which is set out in the Company's Directors' Remuneration Report for 2025.
|
Type |
Name of individual |
Title |
Number of share options granted |
|
LTIP - Grant in respect of 2026 |
Dr. Frank Mathias |
Chief Executive Officer |
478,119 |
|
LTIP - Grant in respect of 2025 |
46,195 |
||
|
LTIP - Grant in respect of 2024 |
43,790 |
||
|
2026 DBP |
Dr. Frank Mathias |
Chief Executive Officer |
71,891 |
|
LTIP - Grant in respect of 2026 |
Dr. Lucinda Crabtree |
Chief Financial Officer |
156,884 |
|
LTIP - Grant in respect of 2025 |
26,526 |
||
|
LTIP - Grant in respect of 2024 |
12,876 |
||
|
2026 DBP |
Dr. Lucinda Crabtree |
Chief Financial Officer |
47,179 |
|
LTIP - Grant in respect of 2026 |
Natalie Walter |
Chief Legal Officer and Group Company Secretary |
75,479 |
|
2026 DBP |
Natalie Walter |
Chief Legal Officer and Group Company Secretary |
12,459 |
|
LTIP - Grant in respect of 2026 |
Dr. Kyriacos Mitrophanous |
Chief Innovation Officer |
72,391 |
|
2026 DBP |
Dr. Kyriacos Mitrophanous |
Chief Innovation Officer |
10,841 |
|
LTIP - Grant in respect of 2026 |
Lisa Doman |
Chief People Officer |
69,992 |
|
2026 DBP |
Lisa Doman |
Chief People Officer |
10,629 |
|
LTIP - Grant in respect of 2026 |
Dr. Sébastien Ribault |
Chief Business Officer |
107,102 |
|
2026 DBP |
Dr. Sébastien Ribault |
Chief Business Officer |
14,908 |
|
LTIP - Grant in respect of 2026 |
Mark Caswell |
Site Head, UK Operations |
49,431 |
|
2026 LTIP RSU |
Dr. Sabine Sydow |
Chief of Staff |
7,036 |
|
2026 LTIP RSU |
Dr. Melanie Kearney |
Global Head of Quality |
12,711 |
|
2026 LTIP RSU |
John Foy |
Site Head, Durham Operations |
12,380 |
|
2026 LTIP RSU |
Stéphanie Colloud |
Site Head and General Manager of France Operations |
10,357 |
|
2026 LTIP RSU |
Kathleen Miller |
Head of Human Resources (and acting Interim Site Head, Bedford) |
12,628 |
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||||||||
|
2. |
Reason for the notification |
|||||||||||||
|
a) |
Position/status |
Chief Executive Officer |
||||||||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||||||||
|
b) |
Name of natural person |
Frank Mathias |
||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||||||||
|
b) |
Description of instrument |
Share |
||||||||||||
|
|
|
|||||||||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||||||||
|
e) |
Currency |
GBP - British Pound |
||||||||||||
|
f) |
Nature of the transaction |
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||||||||
|
g) |
Price(s) and volumes(s) |
|
||||||||||||
|
h) |
Aggregated information |
|
||||||||||||
|
- Aggregated volume |
LTIP awards granted over 478,119 shares in total |
|||||||||||||
|
- Price
- Aggregated volume - - Price
- Aggregated volume - Price |
Nil LTIP awards over 46,195 shares in total
Nil LTIP awards over 43,790 shares in total Nil |
|||||||||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Executive Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Frank Mathias |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
DBP awards granted over 71,891 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||||||||
|
2. |
Reason for the notification |
|||||||||||||
|
a) |
Position/status |
Chief Financial Officer |
||||||||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||||||||
|
b) |
Name of natural person |
Lucinda Crabtree |
||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||||||||
|
b) |
Description of instrument |
Share |
||||||||||||
|
|
|
|||||||||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||||||||
|
e) |
Currency |
GBP - British Pound |
||||||||||||
|
f) |
Nature of the transaction |
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||||||||
|
g) |
Price(s) and volumes(s) |
|
||||||||||||
|
h) |
Aggregated information |
|
||||||||||||
|
- Aggregated volume |
LTIP awards granted over 156,884 shares in total |
|||||||||||||
|
- Price
- Aggregated volume - - Price
- Aggregated volume - Price |
Nil LTIP awards over 26,526 shares in total
Nil
LTIP awards over 12,876 shares in total Nil |
|||||||||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Financial Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Lucinda Crabtree |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
DBP awards granted over 47,179 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Legal Officer and Group Company Secretary |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Natalie Walter |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP awards granted over 75,479 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Legal Officer and Group Company Secretary |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Natalie Walter |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
DBP awards granted over 12,459 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Business Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Sébastien Ribault |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP awards granted over 107,102 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Business Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Sébastien Ribault |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
DBP awards granted over 14,908 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief People Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Lisa Doman |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP awards granted over 69,992 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief People Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Lisa Doman |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
DBP awards granted over 10,629 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Innovation Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Kyriacos Mitrophanous |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP awards granted over 72,391 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Innovation Officer |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Kyriacos Mitrophanous |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
DBP awards granted over 10,841 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Site Head, UK Operations |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Mark Caswell |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP awards granted over 49,431 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief of Staff |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Sabine Sydow |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP RSU awards granted over 7,036 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Global Head of Quality |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Melanie Kearney |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP RSU awards granted over 12,711 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Site Head, Durham Operations |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
John Foy |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP RSU awards granted over 12,380 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Site Head and General Manager of France Operations |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Stephanie Colloud |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP RSU awards granted over 10,357 shares in total |
|||||||
|
- Price |
Nil |
|||||||
|
1. |
Details of the Issuer or emission allowance market participant |
|||||||
|
a) |
Full name of the entity |
Oxford Biomedica plc |
||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||
|
2. |
Reason for the notification |
|||||||
|
a) |
Position/status |
Head of Human Resources (and acting Interim Site Head, Bedford) |
||||||
|
b) |
Initial notification / amendment |
Initial Notification |
||||||
|
3. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Is this a PDMR or PCA Submission |
Submission for PDMR |
||||||
|
b) |
Name of natural person |
Kathleen Miller |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Date of the transaction |
2026-04-07 |
||||||
|
b) |
Description of instrument |
Share |
||||||
|
|
|
|||||||
|
c) |
Identification code |
ISIN: GB00BDFBVT43 |
||||||
|
d) |
Place of the transaction |
Outside the trading venue |
||||||
|
e) |
Currency |
GBP - British Pound |
||||||
|
f) |
Nature of the transaction |
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. |
||||||
|
g) |
Price(s) and volumes(s) |
|
||||||
|
h) |
Aggregated information |
|
||||||
|
- Aggregated volume |
LTIP RSU awards granted over 12,628 shares in total |
|||||||
|
- Price |
Nil |
|||||||
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: [email protected]
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.